July 13, 2017 (Source) – BlueOcean NutraSciences Inc. (TSXV:BOC) (“BlueOcean” or the “Company”) is pleased to announce it has retained at no cash cost, the core of the Company’s 2011-13 CO2 gas infusion team to be led by John Archibald, co-founder of BlueOcean, InVentures and Canzone. Mr. Archibald rejoined BlueOcean after selling all gas applications at InVentures and Canzone other than CO2 gas infusion licensed to the Company. His role is to monetize the Company’s CO2 gas infusion license granted by Canzone in 2011 that led to the Company going public in 2012.
Mr. Archibald is working with Dr Matt Julius and St. Cloud U in Minnesota. Dr Julius has significant gas infusion expertise accelerating algae growth. Dr. Julius will head side by side growth trials at St. Cloud and client facilities to determine incremental growth, yield and quality using CO2 gas infused water. The Company’s CO2 gas infusion was first proven at Canada’s NRC’s algae labs in 2009-10 and demonstrated 200%-300% accelerated growth. During tests in 2013 at the University of Guelph the technology demonstrated acceleration of hydroponic lettuce growth by up to 100%. Water foliar spraying of dissolved CO2 targeted at cannabis and other plant leaf stomata accelerates CO2 uptake and therefore should enhance growth rates.
The company’s licensed CO2 gas infusion field of use is for any CO2 infusion into water for the increased growth of any plants and animals. Since 2000, there have been 1600 commercial gas infusion devices installed globally under John’s oversight in mostly dissolved oxygen gas infusion groundwater remediation, aquaculture, fermentation and cosmetics
The Company has the right to sublicense and/or site license and the right to manufacture its own CO2 gas infusion devices. The Company will proceed with paid trials at St Cloud U and other sites such as U of Guelph and as successful, move to larger site growth pilots. If further successful, the Company will enter into royalty arrangements and install and monitor full commercial client CO2 gas infusion applications.
BlueOcean CEO, Dr. Marvin Heuer commented, “The 2011-13 CO2 gas infusion team was initially headed by John Archibald with algae production platform engineering, botany science and gas infusion expertise. All core team members have confirmed interest to return under John to monetize our CO2 gas infusion license. Dissolving CO2 gas into water for foliar spray could accelerate above ground commercial marijuana, cash produce (i.e. lettuce), flowers, urban micro greens and other high value photosynthetic plant growth beyond just algae.”
About Blue Ocean
BlueOcean NutraSciences Inc. is a Canadian public listed company (TSXV:BOC) whose mission is to develop effective, innovative and sustainable products from Natural Sources, to improve the lives of its customers. This includes naturally accelerating plant growth. BlueOcean’s first specialty ingredient is its patent protected shrimp oil which is the base for its current three consumer brands. Shrimp oil is made from sustainably certified North Atlantic cold water shrimp shells (the by-product of the cooked and peeled shrimp process) and contains phospholipid bound omega- fatty acids and over 40 times more natural astaxanthin compared to krill oil ingredients.
Shrimp oil’s unique nutritional properties enables the ingredient to make numerous health claims across a wide range of markets, including the $4Bn omega-3 heart health market, the $9Bn joint health market and the $10Bn sports supplement market. BlueOcean markets its shrimp oil ingredient through a number of consumer brands that are formulated to target these specific markets.
BlueOcean currently markets its shrimp oil under three consumer brands: Pure Polar(R) Omega-3 Shrimp Oil, Joint AXTM and Sport AXTM. Products may be purchased online at purepolarlabs.com.
Its CO2 gas infusion technology under license is being monetized to further support the development of its broadening line of shrimp oil products.
This news release may contain forward-looking statements that are based on BlueOcean’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.